GRM2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL100657	1.00	20/20
SCHEMBL101802	1.00	20/20
SCHEMBL103205	1.00	20/20
SCHEMBL103628	1.00	20/20
SCHEMBL103760	1.00	20/20
SCHEMBL171750	1.00	20/20
SCHEMBL171937	0.84	20/20
SCHEMBL171799	0.82	20/20
SCHEMBL171300	0.81	20/20
SCHEMBL171274	0.79	20/20
SCHEMBL171654	0.78	20/20
SCHEMBL171787	0.77	20/20
SCHEMBL101605	0.77	20/20
SCHEMBL171747	0.74	20/20
SCHEMBL171830	0.74	20/20
SCHEMBL169721	0.72	20/20
SCHEMBL171806	0.72	20/20
SCHEMBL102033	0.71	20/20
SCHEMBL171886	0.71	20/20
SCHEMBL100668	0.71	20/20

Clinical trials — most relevant to GRM2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome	PHASE3	UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
TRPM8 Activators for Peripheral Neuropathy	PHASE2	ACTIVE_NOT_RECRUITING
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression	PHASE1	WITHDRAWN
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers	PHASE1	COMPLETED
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Acamprosate: Genes Associated With Response	nan	COMPLETED
Sleep/Wake Cycle and Depression: An Imaging and Treatment Study	nan	COMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
Metabotropic Receptors For Glutamate Type 3 In Parkinson's	nan	UNKNOWN
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRM2 binder may also engage these)

Protein	Name	Similarity
P31421	—	1.000	P31421 →
Q14BI2	—	1.000	Q14BI2 →
GRM3	Metabotropic glutamate receptor 3	0.984	landscape →
Q1ZZH1	—	0.984	Q1ZZH1 →
Q5RAL3	—	0.983	Q5RAL3 →
Q9QYS2	—	0.982	Q9QYS2 →
GRM1	Metabotropic glutamate receptor 1	0.980	landscape →
Q3UVX5	—	0.980	Q3UVX5 →
GRM5	Metabotropic glutamate receptor 5	0.979	landscape →
P31422	—	0.976	P31422 →
O57329	—	0.976	O57329 →
P16067	—	0.976	P16067 →
Q6VVW5	—	0.975	Q6VVW5 →
P31424	—	0.975	P31424 →
P20594	—	0.974	P20594 →
P97772	—	0.974	P97772 →
FZD7	Frizzled-7	0.973	landscape →
P23385	—	0.973	P23385 →
NPR1	Atrial natriuretic peptide receptor 1	0.972	landscape →
O57328	—	0.972	O57328 →
Q38PU2	—	0.971	Q38PU2 →
Q08464	—	0.971	Q08464 →
G5ECB2	—	0.971	G5ECB2 →
Q14332	—	0.970	Q14332 →
P18537	—	0.970	P18537 →
Q8AVJ9	—	0.970	Q8AVJ9 →
Q61626	—	0.969	Q61626 →
Q61090	—	0.969	Q61090 →
Q9IA06	—	0.969	Q9IA06 →
P18910	—	0.969	P18910 →